Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial

This phase Ib study compared the effects of AZD9977, a selective mineralocorticoid receptor modulator with predicted low hyperkalemia risk, with spironolactone on serum potassium (sK(+)) in patients with heart failure (HF) with preserved or mildly reduced ejection fraction (EF; ≥40%), and renal impa...

Descripción completa

Detalles Bibliográficos
Autores principales: Squire, Iain B., Gabrielsen, Anders, Greasley, Peter J., Wernevik, Linda, Hartleib‐Geschwindner, Judith, Holden, Julie, Johansson, Susanne, Rudvik, Anna, Sánchez, José, Bamberg, Krister, Melin, Johanna, Whittaker, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579384/
https://www.ncbi.nlm.nih.gov/pubmed/35971596
http://dx.doi.org/10.1111/cts.13377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579384/
https://www.ncbi.nlm.nih.gov/pubmed/35971596
http://dx.doi.org/10.1111/cts.13377

Ejemplares similares